

Neural-Tube Defects with Dolutegravir Treatment from

New England Journal of Medicine

379, 979-981

DOI: [10.1056/nejmc1807653](https://doi.org/10.1056/nejmc1807653)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Longitudinal patterns of unmet need for contraception among women living with HIV on antiretroviral therapy in South Africa. PLoS ONE, 2018, 13, e0209114.	1.1	13
2	HIV-1 update 2018. Pharmacy Today, 2018, 24, 51-69.	0.0	1
3	HIV post-exposure prophylaxis (PEP). BMJ: British Medical Journal, 2018, 363, k4928.	2.4	12
4	Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV, 2018, 5, e638-e646.	2.1	56
5	Peri-conceptual dolutegravir use linked with neural tube defects. Reactions Weekly, 2018, 1714, 10-10.	0.0	0
6	Switch to dolutegravir is well tolerated in Thais with HIV infection. Journal of the International AIDS Society, 2019, 22, e25324.	1.2	11
7	The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. Infectious Diseases of Poverty, 2019, 8, 63.	1.5	25
8	Pretreatment HIV drug resistance in low- and middle-income countries. Future Virology, 2019, 14, 427-440.	0.9	3
9	Antiretroviral Medications for the Prevention of HIV Infection. Infectious Disease Clinics of North America, 2019, 33, 629-646.	1.9	6
10	The Reproductive Years of Women with Perinatally Acquired HIV. Infectious Disease Clinics of North America, 2019, 33, 817-833.	1.9	3
11	Pediatric Antiretroviral Therapy. Handbook of Experimental Pharmacology, 2019, 261, 285-323.	0.9	3
12	Dolutegravir Use at Conception – Additional Surveillance Data from Botswana. New England Journal of Medicine, 2019, 381, 885-887.	13.9	36
13	Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. New England Journal of Medicine, 2019, 381, 827-840.	13.9	269
14	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. Journal of the International AIDS Society, 2019, 22, e25352.	1.2	25
15	Global HIV Treatment – Turning Headwinds to Tailwinds. New England Journal of Medicine, 2019, 381, 873-874.	13.9	7
16	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine, 2019, 381, 803-815.	13.9	447
17	Health Care Autonomy of Women Living with HIV. New England Journal of Medicine, 2019, 381, 798-800.	13.9	3
19	Why Everyone (Almost) with HIV Needs to Be on Treatment. Infectious Disease Clinics of North America, 2019, 33, 663-679.	1.9	8

#	ARTICLE	IF	CITATIONS
20	Maternal Use of Antiviral Drugs, Immune Globulins, or Vaccines and Infant Congenital Malformations. , 2019, , 181-195.		0
21	Management of Virologic Failure and HIV Drug Resistance. Infectious Disease Clinics of North America, 2019, 33, 707-742.	1.9	40
22	Initial Antiretroviral Therapy in an Integrase Inhibitor Era. Infectious Disease Clinics of North America, 2019, 33, 681-692.	1.9	6
23	Contemporary Issues in Pregnancy (and Offspring) in the Current HIV Era. Current HIV/AIDS Reports, 2019, 16, 492-500.	1.1	13
24	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. Journal of the International AIDS Society, 2019, 22, e25381.	1.2	13
25	Neural tube defect diagnosis and outcomes at a tertiary South African hospital with intensive case ascertainment. South African Medical Journal, 2019, 109, 698.	0.2	7
26	Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. Lancet HIV, the, 2019, 6, e552-e558.	2.1	24
27	Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Alimentary Pharmacology and Therapeutics, 2019, 50, 738-750.	1.9	35
28	Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors. Frontiers in Microbiology, 2019, 10, 1877.	1.5	22
29	Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition. Journal of Biological Chemistry, 2019, 294, 15137-15157.	1.6	57
30	Why South Africa urgently needs to support the development of pregnancy exposure registries. South African Medical Journal, 2019, 109, 294.	0.2	3
31	Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors. AIDS Reviews, 2019, 21, 4-10.	0.5	70
32	Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Medicine, 2019, 16, e1002895.	3.9	58
33	Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821986732.	0.6	11
34	Use of Dolutegravir for Antiretroviral Therapy for Women of Childbearing Age. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2019, 48, 664-673.	0.2	0
35	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	1.2	46
36	Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Expert Opinion on Pharmacotherapy, 2019, 20, 385-397.	0.9	17
37	Choosing appropriate pharmacotherapy for drug-resistant HIV. Expert Opinion on Pharmacotherapy, 2019, 20, 667-678.	0.9	10

#	ARTICLE	IF	CITATIONS
38	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 253-264.	4.6	114
39	Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 1338-1345.	1.1	23
40	HIV Screening and Preexposure Prophylaxis Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2172.	3.8	6
41	Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. <i>Drug Metabolism and Disposition</i> , 2019, 47, 890-898.	1.7	21
42	Co-formulated bicitegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV</i> , the, 2019, 6, e364-e372.	2.1	102
43	A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia. <i>Drug Safety</i> , 2019, 42, 915-917.	1.4	3
44	Real life use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. <i>PLoS ONE</i> , 2019, 14, e0216010.	1.1	3
45	Treatment of Viral Infections During Pregnancy. <i>Clinics in Perinatology</i> , 2019, 46, 235-256.	0.8	12
46	A Multicenter Analysis of Elvitegravir Use During Pregnancy on HIV Viral Suppression and Perinatal Outcomes. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz129.	0.4	7
47	Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e246-e252.	4.6	41
48	High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2030-2038.	1.3	6
49	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naïve Adults in South Africa, 2000–2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	3.2	51
50	Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?. <i>Pharmacotherapy</i> , 2019, 39, 576-598.	1.2	41
51	Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. <i>Lancet HIV</i> , the, 2019, 6, e201-e204.	2.1	24
52	British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. <i>HIV Medicine</i> , 2019, 20, s2-s85.	1.0	31
53	Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12
54	The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. <i>Infection and Chemotherapy</i> , 2019, 51, 77.	1.0	12
55	HIV Eradication Strategies: Implications for the Central Nervous System. <i>Current HIV/AIDS Reports</i> , 2019, 16, 96-104.	1.1	27

#	ARTICLE	IF	CITATIONS
56	Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV. <i>Annals of Pharmacotherapy</i> , 2019, 53, 833-844.	0.9	12
57	High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up. <i>AIDS Research and Therapy</i> , 2019, 16, 5.	0.7	12
58	A proposal for the systematic assessment of data quality indicators in birth defects surveillance. <i>Birth Defects Research</i> , 2019, 111, 324-332.	0.8	2
59	Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model. <i>Translational Psychiatry</i> , 2019, 9, 84.	2.4	9
60	Cohort profile: The Observational cohort for the study of DOLutegravir in Antiretroviral Combination REgimens (ODOACRE). <i>BMJ Open</i> , 2019, 9, e029960.	0.8	12
61	Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential. <i>Annals of Internal Medicine</i> , 2019, 170, 614.	2.0	48
62	Decision Making in a Time of Uncertainty: Dolutegravir for Reproductive-Age Women. <i>Annals of Internal Medicine</i> , 2019, 170, 658.	2.0	4
63	The impact of health programmes to prevent vertical transmission of HIV. Advances, emerging health challenges and research priorities for children exposed to or living with HIV: Perspectives from South Africa. <i>South African Medical Journal</i> , 2019, 109, 77.	0.2	12
64	Novel mouse model of encephalocele: post-neurulation origin and relationship to open neural tube defects. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	20
65	Growth and Neurodevelopment of HIV-Exposed Uninfected Children: a Conceptual Framework. <i>Current HIV/AIDS Reports</i> , 2019, 16, 501-513.	1.1	74
66	Protecting Mothers and Babies: A Delicate Balancing Act. <i>Obstetric Anesthesia Digest</i> , 2019, 39, 15-17.	0.0	0
67	HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru. <i>Journal of the International AIDS Society</i> , 2019, 22, e25411.	1.2	9
68	Dolutegravir: advancing ethical research in pregnancy. <i>Lancet, The</i> , 2019, 394, 1972-1974.	6.3	9
69	Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008â€“2018. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 264-268.	0.9	19
70	Update on HIV integrase inhibitors for the treatment of HIV-1 infection. <i>Future Virology</i> , 2019, 14, 693-709.	0.9	6
71	Antiviral drugs. <i>Side Effects of Drugs Annual</i> , 2019, , 301-319.	0.6	4
72	Update on Adverse Effects of HIV Integrase Inhibitors. <i>Current Treatment Options in Infectious Diseases</i> , 2019, 11, 372-387.	0.8	51
73	Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 41-45.	0.9	7

#	ARTICLE	IF	CITATIONS
74	Single-Tablet Combination Therapy for HIV Infection in Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 804-815.	0.6	2
75	In Utero Efavirenz Exposure and Neurodevelopmental Outcomes in HIV-exposed Uninfected Children in Botswana. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 828-834.	1.1	32
76	DÃ©jÃ vu all over again. <i>Aids</i> , 2019, 33, 2097-2098.	1.0	0
77	Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1129-1143.	1.3	16
78	The antagonism of folate receptor by dolutegravir. <i>Aids</i> , 2019, 33, 1967-1976.	1.0	31
79	Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 247-250.	0.9	13
80	Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 481-486.	0.9	17
81	Reaching 90â€“90â€“90 in Botswana. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 442-448.	1.5	15
82	Perinatal outcomes associated with maternal HIV and antiretroviral therapy in pregnancies with accurate gestational age in South Africa. <i>Aids</i> , 2019, 33, 1623-1633.	1.0	38
83	Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 321-328.	0.9	34
84	Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. <i>Aids</i> , 2019, 33, 1797-1799.	1.0	6
85	Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 316-324.	0.9	9
86	Does Changing Antiretroviral Therapy in the First Trimester of Pregnancy for Safety Concerns Have an Impact on Viral Suppression?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 574-584.	0.9	4
87	Modern Human Immunodeficiency Virus Therapy: Progress and Prospects. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 61-70.	2.3	15
88	Dolutegravir in sub-Saharan Africa: context is crucial. <i>Lancet HIV</i> , 2019, 6, e72-e73.	2.1	14
89	Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. <i>Clinical Infectious Diseases</i> , 2020, 70, 2599-2606.	2.9	13
90	Fertility Intentions and Clinical Care Attendance Among Women Living with HIV in South Africa. <i>AIDS and Behavior</i> , 2020, 24, 1585-1591.	1.4	4
91	Effect of HIV Infection and Antiretroviral Treatment on Pregnancy Rates in the Western Cape Province of South Africa. <i>Journal of Infectious Diseases</i> , 2020, 221, 1953-1962.	1.9	8

#	ARTICLE	IF	CITATIONS
92	Human Immunodeficiency Virus, Antiretroviral Therapy, and Fertility in Sub-Saharan Africa: Pieces Still Missing in the Jigsaw Puzzle. <i>Journal of Infectious Diseases</i> , 2020, 221, 1919-1921.	1.9	1
93	Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings. <i>Clinical Infectious Diseases</i> , 2020, 71, e170-e177.	2.9	4
94	Women living with HIV in high-income settings and breastfeeding. <i>Journal of Internal Medicine</i> , 2020, 287, 19-31.	2.7	13
95	Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients. <i>Annals of Pharmacotherapy</i> , 2020, 54, 633-643.	0.9	7
96	Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating <i>Ex Vivo</i> Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1352-1361.	2.3	30
97	Absence of developmental and reproductive toxicity in animals exposed to dolutegravir. <i>Birth Defects Research</i> , 2020, 112, 245-261.	0.8	13
98	Mini review: Prevention of mother-child transmission of HIV: 25 years of continuous progress toward the eradication of pediatric AIDS?. <i>Virulence</i> , 2020, 11, 14-22.	1.8	8
99	Letter to the editor re. <i>Aids</i> , 2020, 34, 162-163.	1.0	1
100	Safety implications of combined antiretroviral and anti-tuberculosis drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 23-41.	1.0	24
101	HIV treatment and prevention 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 4-12.	1.5	52
102	HIV postexposure prophylaxis-in-pocket: long-term follow-up of individuals with low-frequency, high-risk HIV exposures. <i>Aids</i> , 2020, 34, 433-437.	1.0	10
103	Global public health efforts to address HIV and related communicable disease syndemics. <i>Current Opinion in HIV and AIDS</i> , 2020, Publish Ahead of Print, 261-265.	1.5	4
105	Efectividad y seguridad de inhibidores de integrasa en la gestante con infección VIH en la Cohorte de embarazadas de la Comunidad de Madrid. <i>Medicina Clínica</i> , 2020, 155, 441-444.	0.3	2
106	Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected. <i>Aids</i> , 2020, 34, 1377-1387.	1.0	19
107	Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3319-3326.	1.3	9
109	Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir. <i>Aids</i> , 2020, 34, 2137-2139.	1.0	2
110	Post-exposure prophylaxis for Blood-Borne Viral (BBV) Infections. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 83-91.	0.5	3
111	Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3525-3533.	1.3	12

#	ARTICLE	IF	CITATIONS
112	The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women. <i>Drug Safety</i> , 2020, 43, 1133-1140.	1.4	5
113	The Intergenerational Impact of a Slow Pandemic: HIV and Children. <i>New Directions for Child and Adolescent Development</i> , 2020, 2020, 139-150.	1.3	1
114	HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy. <i>South African Medical Journal</i> , 2020, 110, 827.	0.2	1
115	HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. <i>Drugs</i> , 2020, 80, 1649-1676.	4.9	62
116	Significant Publications on Infectious Diseases Pharmacotherapy in 2019. <i>Journal of Pharmacy Practice</i> , 2021, 34, 800-813.	0.5	2
117	Accelerating progress towards the elimination of mother-to-child transmission of HIV: a narrative review. <i>Journal of the International AIDS Society</i> , 2020, 23, e25571.	1.2	25
118	Effectiveness and safety of integrase inhibitors in HIV-infected pregnant women followed up in the Madrid Cohort. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 441-444.	0.1	0
119	Weight gain during pregnancy among women initiating dolutegravir in Botswana. <i>EClinicalMedicine</i> , 2020, 29-30, 100615.	3.2	21
120	Nothing is perfect: the safety issues of integrase inhibitor regimens. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 683-694.	1.0	8
121	Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. <i>PLoS ONE</i> , 2020, 15, e0233693.	1.1	0
122	Combination therapy against human infections caused by viruses. , 2020, , 183-205.		0
123	Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612092017.	1.1	18
124	An update on maternal medication-related embryopathies. <i>Prenatal Diagnosis</i> , 2020, 40, 1168-1177.	1.1	4
125	Human Immunodeficiency Virus in Adolescents. <i>Primary Care - Clinics in Office Practice</i> , 2020, 47, 351-365.	0.7	0
126	Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy. <i>Contraception</i> , 2020, 102, 174-179.	0.8	8
127	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. <i>MSphere</i> , 2020, 5, .	1.3	2
128	Dolutegravir and neural tube defects: a new insight. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 405-406.	4.6	14
129	Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. <i>EClinicalMedicine</i> , 2020, 22, 100355.	3.2	5

#	ARTICLE	IF	CITATIONS
130	The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 121-127.	2.9	13
131	Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, e2-e5.	0.9	5
132	Recent Advances in the Development of Integrase Inhibitors for HIV Treatment. <i>Current HIV/AIDS Reports</i> , 2020, 17, 63-75.	1.1	22
133	The potential role of bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. <i>HIV Medicine</i> , 2020, 21, 3-16.	1.0	17
134	The management of treatment-experienced HIV patients (including virologic failure and switches). <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612090139.	1.1	12
135	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
136	Pharmacokinetics of HIV therapies in pregnant patients: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 449-461.	1.5	2
137	Codesigning care improvements for women living with HIV: a patient-oriented deliberative dialogue workshop in Montréal, Quebec. <i>CMAJ Open</i> , 2020, 8, E264-E272.	1.1	8
138	Dolutegravir for pregnant women living with HIV. <i>Cmaj</i> , 2020, 192, E217-E218.	0.9	6
139	The far-reaching HAND of cART: cART effects on astrocytes. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 144-158.	2.1	19
140	Trajectories of fertility intentions among women living with HIV in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 180-186.	0.6	1
141	HIV in pregnancy – An update. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 256, 484-491.	0.5	25
142	Global emerging resistance in pediatric infections with TB, HIV, and gram-negative pathogens. <i>Paediatrics and International Child Health</i> , 2021, 41, 65-75.	0.3	7
143	Differential effects of antiretroviral drug toxicity in male versus female children who are HIV-exposed but uninfected. <i>Aids</i> , 2021, 35, 1-14.	1.0	4
144	Frequency of differential placental transfer to twins of maternal antiretroviral medications. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 256, 405-411.	0.5	2
145	Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 90-112.	2.1	44
146	Evaluating Neurodevelopmental Consequences of Perinatal Exposure to Antiretroviral Drugs: Current Challenges and New Approaches. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 113-129.	2.1	26
147	CNS Neurotoxicity of Antiretrovirals. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 130-143.	2.1	58

#	ARTICLE	IF	CITATIONS
148	Pharmacokinetics and placental transfer of dolutegravir in pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 283-289.	1.3	1
149	Lessons from dolutegravir and neural tube defects. <i>Lancet HIV</i> , 2021, 8, e3-e4.	2.1	4
150	Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. <i>BMJ Case Reports</i> , 2021, 14, e236655.	0.2	3
151	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. <i>Aids</i> , 2021, 35, 205-211.	1.0	11
152	Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1397-1409.	0.9	13
153	AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial. <i>Wellcome Open Research</i> , 0, 6, 33.	0.9	4
154	Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy. <i>Aids</i> , 2021, 35, 219-226.	1.0	17
155	Unintended pregnancy and viral suppression in pregnant women living with HIV. <i>American Journal of Obstetrics & Gynecology</i> MFM, 2021, 3, 100300.	1.3	8
156	Two cases of neural tube defects with dolutegravir use at conception in south Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101572.	0.3	6
157	Impact of pre-existing drug resistance on risk of virological failure in South Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1558-1563.	1.3	13
158	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 1276-1292.	6.3	82
159	ART in pregnant women living with HIV. <i>Lancet, The</i> , 2021, 397, 1240-1241.	6.3	2
160	Ethical considerations for research involving pregnant women living with HIV and their young children: a systematic review of the empiric literature and discussion. <i>BMC Medical Ethics</i> , 2021, 22, 38.	1.0	6
161	The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study. <i>PLoS ONE</i> , 2021, 16, e0246766.	1.1	0
162	Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy. <i>PLoS ONE</i> , 2021, 16, e0251746.	1.1	12
163	Neurological development of children who are HIV-exposed and uninfected. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 1161-1170.	1.1	9
164	Maternal Intervention to Prevent Mother-to-Child Transmission of HIV: Moving Beyond Antiretroviral Therapy. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, S5-S10.	1.1	4
165	Ethical issues in therapeutic use and research in pregnant and breastfeeding women. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 7-21.	1.1	28

#	ARTICLE	IF	CITATIONS
166	The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy. <i>Journal of Midwifery and Women's Health</i> , 2021, 66, 403-406.	0.7	3
167	A Bayesian nonparametric approach for inferring drug combination effects on mental health in people with HIV. <i>Biometrics</i> , 2022, 78, 988-1000.	0.8	4
168	Hepatitis B and C infections in HIV-1 patients on combination antiretroviral therapy (cART) in Ghana: implications for immunologic recovery, clinical response to treatment, and hepatotoxicity. <i>Heliyon</i> , 2021, 7, e07172.	1.4	6
169	InÂvitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. <i>HIV Medicine</i> , 2021, 22, 898-906.	1.0	1
170	Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. <i>Molecular Neurobiology</i> , 2021, 58, 5703-5721.	1.9	12
171	Pregnancies among women living with HIV using contraceptives and antiretroviral therapy in western Kenya: a retrospective, cohort study. <i>BMC Medicine</i> , 2021, 19, 178.	2.3	4
172	Assessing the capacity and findings of routine programmatic data in Kenya to guide decision-making around contraceptives and antiretroviral therapy. <i>BMC Medicine</i> , 2021, 19, 192.	2.3	1
173	Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone. <i>Genes</i> , 2021, 12, 1314.	1.0	3
174	Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity. <i>Toxicological Sciences</i> , 2021, 184, 191-203.	1.4	10
175	HIV-1 persistence in the CNS: Mechanisms of latency, pathogenesis and an update on eradication strategies. <i>Virus Research</i> , 2021, 303, 198523.	1.1	17
176	HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166206.	1.8	15
177	Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. <i>Viruses</i> , 2021, 13, 205.	1.5	42
178	Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. <i>Lancet HIV</i> , 2021, 8, e33-e41.	2.1	32
179	ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. <i>BMC Infectious Diseases</i> , 2021, 21, 5.	1.3	26
180	Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels. <i>EBioMedicine</i> , 2021, 63, 103167.	2.7	25
182	Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) â€” Protocol and data analysis plan for a cohort study. <i>Wellcome Open Research</i> , 0, 4, 34.	0.9	4
183	Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection â€” 15 Jurisdictions, 2013â€”2017. <i>Morbidity and Mortality Weekly Report</i> , 2020, 69, 1-5.	9.0	51
184	Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV. <i>Current Pharmaceutical Design</i> , 2019, 25, 556-576.	0.9	13

#	ARTICLE	IF	CITATIONS
185	Guidelines to support HIV-affected individuals and couples to achieve pregnancy safely: Update 2018. Southern African Journal of HIV Medicine, 2018, 19, 915.	0.3	25
186	Birth outcomes following antiretroviral exposure during pregnancy: Initial results from a pregnancy exposure registry in South Africa. Southern African Journal of HIV Medicine, 2019, 20, 971.	0.3	16
187	Patterns of changing pregnancy intentions among women living with HIV in Canada. BMC Women's Health, 2021, 21, 350.	0.8	4
188	Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). HIV Medicine, 2022, 23, 287-293.	1.0	16
189	A practical clinical guide to counselling on and managing contraception, pre-conception planning, and menopause for women living with HIV. Jammi, O, , .	0.3	0
191	Adverse effects of using dolutegravir HIV in pregnant women and their newborn. Obstetrics & Gynecology International Journal, 2019, 10, .	0.0	0
193	Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications. Pan African Medical Journal, 2020, 37, 243.	0.3	1
196	Perinatal outcomes of twenty-five human immunodeficiency virus-infected pregnant women: Hacettepe University experience. Journal of the Turkish German Gynecology Association, 2020, 21, 180-186.	0.2	4
198	Prevalence of neural tube defects, maternal <sc>HIV</sc> status, and antiretroviral therapy from a hospital-based birth defect surveillance in Kampala, Uganda. Birth Defects Research, 2022, 114, 95-104.	0.8	5
199	Principles of HIV Treatment. , 2022, , 391-413.		0
200	HIV Testing and Prevention. , 2022, , 23-43.		0
201	Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity. Annals of Internal Medicine, 2022, 175, 84-94.	2.0	12
202	Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report. Journal of Antimicrobial Chemotherapy, 2022, 77, 851-853.	1.3	3
203	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naïve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases, 2022, 9, ofab595.	0.4	3
204	Dolutegravir and rat whole embryo culture. Birth Defects Research, 2022, 114, 23-24.	0.8	3
205	Fetal-Maternal Surgery for Spina Bifida in a HIV-Infected Mother. Fetal Diagnosis and Therapy, 2022, 49, 25-28.	0.6	2
206	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. Aids, 2022, 36, 277-286.	1.0	5
207	Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta. EBioMedicine, 2022, 75, 103771.	2.7	15

#	ARTICLE	IF	CITATIONS
208	Early structural brain development in infants exposed to HIV and antiretroviral therapy <i>in utero</i> in a South African birth cohort. <i>Journal of the International AIDS Society</i> , 2022, 25, e25863.	1.2	14
209	Polyunsaturated Fatty Acid Composition in Breast Milk Plasma of HIV-infected and Uninfected Mothers in Relation to Infant Clinical Outcomes. <i>Nutrition and Metabolic Insights</i> , 2022, 15, 117863882110727.	0.8	2
210	Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 491-509.	1.1	31
211	Integrase Inhibitors Use for HIV Infection in Pregnancy. <i>Current Infectious Disease Reports</i> , 2022, 24, 9-19.	1.3	1
212	UK guideline for the use of HIV post-exposure prophylaxis 2021. <i>HIV Medicine</i> , 2022, 23, 494-545.	1.0	10
213	Trends in antiretroviral use in pregnancy in the UK and Ireland, 2008-2018. <i>HIV Medicine</i> , 2022, 23, 397-405.	1.0	6
214	Low Rates of Contraception Use in Women With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac113.	0.4	2
215	BAGEL: A Bayesian graphical model for inferring drug effect longitudinally on depression in people with HIV. <i>Annals of Applied Statistics</i> , 2022, 16, .	0.5	2
216	Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population-based cohort study. <i>HIV Medicine</i> , 2022, 23, 1007-1018.	1.0	6
217	Impact of Integrase Strand Transfer Inhibitor Use During Pregnancy on Viral Suppression at Delivery and Infant Outcomes: A Statewide Retrospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 448-453.	0.9	3
218	Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. <i>Drug and Therapeutics Bulletin</i> , 2021, , dtb-2021-236655rep.	0.3	0
221	Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 485-500.	2.3	27
222	Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
223	Birth prevalence of neural tube defects in eastern Africa: a systematic review and meta-analysis. <i>BMC Neurology</i> , 2022, 22, .	0.8	11
224	Prescribing patterns of antiretroviral treatments during pregnancy for women living with <sc>HIV</sc> in Canada 2004-2020: A surveillance study. <i>HIV Medicine</i> , 2023, 24, 130-138.	1.0	3
225	Cohort profile: the Western Cape Pregnancy Exposure Registry (WCPER). <i>BMJ Open</i> , 2022, 12, e060205.	0.8	2
226	Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	8
227	The Potential of <i>Spirulina platensis</i> to Ameliorate the Adverse Effects of Highly Active Antiretroviral Therapy (HAART). <i>Nutrients</i> , 2022, 14, 3076.	1.7	5

#	ARTICLE	IF	CITATIONS
228	Antiretroviral Therapy for Children and Newborns. , 2021, , 263-273.		0
229	Prescribing Antiretroviral Therapy. , 2021, , 189-198.		0
230	Using 2D and 3D pluripotent stem cell models to study neurotropic viruses. <i>Frontiers in Virology</i> , 0, 2, .	0.7	3
231	Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth. <i>Nature Communications</i> , 2022, 13, .	5.8	1
232	Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	1
233	Breastfeeding and women living with HIV: Is it possible to move beyond the avoidance?. <i>Journal of HIV for Clinical and Scientific Research</i> , 2022, 9, 005-009.	0.3	0
234	Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. <i>New England Journal of Medicine</i> , 2022, 387, 799-809.	13.9	12
235	Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse Models. <i>Journal of Infectious Diseases</i> , 2022, 226, 1992-2001.	1.9	6
237	A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. <i>Retrovirology</i> , 2022, 19, .	0.9	22
239	HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis. <i>PLOS Global Public Health</i> , 2022, 2, e0000826.	0.5	5
240	Infant HIV Testing Amid the COVID-19 Pandemic and Evolving PMTCT Guidelines in Johannesburg, South Africa. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 302.	0.9	2
241	Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and PBMC. <i>Aids</i> , 0, Publish Ahead of Print, .	1.0	2
242	Epidemiology and Prevention of HIV Infection in Infants, Children, and Adolescents. , 2023, , 681-684.e4.		0
244	HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment. <i>Pharmaceuticals</i> , 2022, 15, 1533.	1.7	4
245	Contraception use and HIV outcomes among women initiating dolutegravir-containing antiretroviral therapy in Kenya: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	0
246	Cabotegravir Exposure of Zebrafish (<i>Danio rerio</i>) Embryos Impacts on Neurodevelopment and Behavior. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1994.	1.8	4
247	New science, drug regulation, and emergent public health issues: The work of FDA's division of applied regulatory science. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
248	Antiretroviral Options and Treatment Decisions During Pregnancy. <i>Paediatric Drugs</i> , 2023, 25, 267-282.	1.3	0

#	ARTICLE	IF	CITATIONS
249	Unplanned pregnancies and social and partner support during pregnancy in Spanish women living with HIV. <i>HIV Medicine</i> , 2023, 24, 727-737.	1.0	1
250	Frequent first-trimester pregnancy loss in rhesus macaques infected with African-lineage Zika virus. <i>PLoS Pathogens</i> , 2023, 19, e1011282.	2.1	5
279	An overview of the mechanisms of HIV-1 infection, latency, pathogenesis, and eradication strategies from the CNS. , 2024, , 1-22.		0